MBL AD Summit 2008

Rapid progress is being made in the diagnosis and treatment of Alzheimer's disease (AD). New office-based techniques have simplified the detection of cognitive impairment and AD. Imaging techniques have advanced and now provide specific information on diagnosis of dementia and recognition of mild cognitive impairment in the earliest phases of AD. Magnetic resonance imaging, glucose positron emission technology, and amyloid imaging each make unique contributions to the diagnosis and characterization of dementia syndromes. Insight into the molecular pathology of AD has identified compounds with great therapeutic promise as well as new treatment targets. The optimal use of current AD therapies can substantially assist the patient in improving the symptoms or delaying the decline of function associated with the disease. Anti-amyloid and neuroprotective agents are currently in advanced stages of preclinical development.

The Alzheimer’s Disease Summit, to take place on May 3, 2008 at the Park Hyatt in Washington, DC, will provide an educational and comprehensive update of recent advances in AD diagnosis and management. Leading experts in the field, Jeffrey L. Cummings, MD, and Pierre N. Tariot, MD, will assemble an expert faculty that will cover a broad array of urgent topics in AD diagnosis and treatment. These key opinion leaders will give brief lectures focused on the principal clinically relevant questions surrounding their respective topics. There will be an opportunity for dialogue with each expert via question-and-answer sessions. At the end of the day, a panel discussion will allow another opportunity for communication with the experts.

The panelists will be joined by Russell Katz, MD, Director of Neurology Products, United States Food and Drug Administration, who will provide an update on topics relevant to drug development and emerging therapies for AD. Participants will gain insight into how the FDA views important topics in drug development for AD.

Overall, participants will gain an improved understanding of how to recognize dementia, diagnose AD, and provide excellent treatment to AD patients and their families, as well as learn about the major areas of research where new treatment advances are anticipated.

Register Now


Jointly sponsored by the Mount Sinai School of Medicine and MBL Communications 7.25 CME AMA PRA Category 1 Credits™ Available CME Course Director Eric Hollander, MD Chair and Professor of Psychiatry Mount Sinai School of Medicine Acknowledgment of Commercial Support This activity is supported in part by educational grants from: